Advertisement
INSM or IONS or PFE
Which Stock Would AI Choose? Insmed (INSM) vs. Ionis Pharmaceuticals (IONS) vs. Pfizer (PFE) Stock Comparison
Key Takeaways
- INSM has delivered robust one-year gains exceeding 85%, fueled by strong revenue growth from BRINSUPRI and ARIKAYCE, though YTD performance shows recent pullback amid pipeline setbacks.
- IONS boasts impressive one-year returns around 119%, supported by revenue expansion to $944 million in 2025 and advancing RNA-targeted therapies like olezarsen.
- PFE offers stability with a high dividend yield over 6% and YTD gains near 8-11%, but trails biotechs in growth amid post-COVID revenue normalization.
- Biotechs INSM and IONS exhibit higher volatility and growth potential in rare diseases, contrasting PFE's diversified pharma scale.
- Recent market activity highlights INSM and IONS momentum from product launches, while PFE benefits from pipeline resilience.
- Valuation contrasts: INSM trades at high price-to-sales due to growth prospects, IONS reflects pipeline value, and PFE appears more affordable on P/E basis.
Introduction
This stock comparison examines INSM, IONS, and PFE, representing biotech innovators and a pharma giant. INSM and IONS focus on rare diseases via targeted therapies, while PFE provides broad exposure to vaccines, oncology, and more. Traders seeking high-growth plays in biotech may eye the former for momentum, whereas investors prioritizing dividends and stability might prefer PFE. Recent performance reflects sector dynamics, with biotechs riding product catalysts amid volatile sentiment, aiding informed relative performance analysis in today's market.
INSM Overview and Recent Performance
Insmed Incorporated (INSM) is a biopharmaceutical firm developing therapies for serious rare diseases, particularly respiratory conditions. Its approved products include ARIKAYCE for refractory nontuberculous mycobacterial lung infections and BRINSUPRI (brensocatib) for non-cystic fibrosis bronchiectasis, recently approved in Europe.
In recent market activity, INSM shares have shown strength, with one-year returns surpassing 85% driven by full-year 2025 revenues of $606.4 million, exceeding expectations, and 2026 BRINSUPRI guidance of at least $1 billion. ARIKAYCE grew 19% annually. Price targets rose to $211 amid launch success, though sentiment dipped on a phase 2 sinusitis study failure, contributing to YTD declines around 20%. Momentum stems from commercial traction and pipeline progress in pulmonary therapies.
IONS Overview and Recent Performance
Ionis Pharmaceuticals, Inc. (IONS) pioneers RNA-targeted medicines for neurological, cardiometabolic, and rare diseases. Marketed products include TRYNGOLZA for familial chylomicronemia syndrome, DAWNZERA for hereditary angioedema, and WAINUA for ATTRv-PN, with SPINRAZA royalties.
Recent weeks have seen IONS deliver one-year gains near 119%, bolstered by 2025 revenues of $944 million, up 34%, and Q4 at $203 million. TRYNGOLZA posted $108 million in first-year sales. Pipeline advances, including olezarsen sNDA for severe hypertriglyceridemia and positive hepatitis B data, have lifted sentiment. YTD returns hover positive amid broader biotech rotation, with focus on 20% revenue growth outlook.
PFE Overview and Recent Performance
Pfizer Inc. (PFE) is a global biopharmaceutical leader with a diverse portfolio spanning vaccines like Prevnar, oncology, cardiovascular, and immunology drugs including Eliquis and Paxlovid.
In recent market activity, PFE has gained 8-11% YTD and around 9% over one year, supported by 6% non-COVID growth and stable dividends yielding over 6%. Shares trade near $26.50-$27, reflecting resilience despite revenue dips from COVID products. Pipeline expansions in oncology and trials signal future drivers, with analyst focus on cost management and M&A. Sentiment remains steady in a maturing post-pandemic landscape.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases top-performing AI trading bots curated from hundreds available on the platform, which collectively trade thousands of tickers across diverse strategies, timeframes, and styles. Only the most suitable for current conditions—based on metrics like annualized returns up to +208%, win rates of 52-95%, and profit factors exceeding 2.5—earn a spot in this dynamic section. For instance, bots in semiconductors boast +90% annualized returns with 60% win rates over hundreds of trades, while others in aerospace hit +72% with 80% wins. A biotech-focused bot trades the BIB ETF, aligning with sector trends. These tools offer pattern recognition, swing trading, and hedging, with stats like profit-to-drawdown ratios up to 22. Explore Trending AI Robots to identify bots matching your risk profile and market view.
Head-to-Head Comparison
INSM and IONS emphasize niche rare disease therapies—INSM in respiratory via DPP1 inhibitors, IONS in RNA-targeting for neurology and cardio—driving higher growth (INSM revenues doubled guidance, IONS up 34%) but elevated risk from clinical dependencies. PFE's broad model spans blockbusters like Prevnar, offering scale ($63B+ revenues) and dividends, yet faces patent cliffs.
Momentum favors biotechs: INSM +85% 1Y, IONS +119% vs. PFE +9%, though PFE shows lower beta (0.41). Risks: Biotechs vulnerable to trial failures (e.g., INSM sinus study), PFE to generic erosion. Sector exposure ties all to healthcare sentiment, with biotechs sensitive to catalysts, PFE to macro stability. Valuations reflect: INSM PS 49x on growth bets, IONS pipeline premium, PFE P/E ~19x more grounded.
Tickeron AI Verdict
Tickeron’s AI currently leans toward INSM for its trend consistency in recent commercial ramps and relative biotech positioning, with BRINSUPRI's $1B+ guidance signaling catalysts amid strong one-year momentum. IONS follows closely on pipeline breadth, while PFE suits stability seekers. Probabilistic edge favors growth-oriented plays in biotech, contingent on sustained launches and trial readouts.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
INSM’s FA Score shows that 0 FA rating(s) are green whileIONS’s FA Score has 0 green FA rating(s), and PFE’s FA Score reflects 1 green FA rating(s).
- INSM’s FA Score: 0 green, 5 red.
- IONS’s FA Score: 0 green, 5 red.
- PFE’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
INSM’s TA Score shows that 3 TA indicator(s) are bullish while IONS’s TA Score has 4 bullish TA indicator(s), and PFE’s TA Score reflects 4 bullish TA indicator(s).
- INSM’s TA Score: 3 bullish, 7 bearish.
- IONS’s TA Score: 4 bullish, 4 bearish.
- PFE’s TA Score: 4 bullish, 4 bearish.
Price Growth
INSM (@Biotechnology) experienced а -5.51% price change this week, while IONS (@Biotechnology) price change was -0.11% , and PFE (@Pharmaceuticals: Major) price fluctuated +0.66% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +3.86%. For the same industry, the average monthly price growth was +11.41%, and the average quarterly price growth was +11.06%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.10%. For the same industry, the average monthly price growth was +4.00%, and the average quarterly price growth was +7.09%.
Reported Earning Dates
INSM is expected to report earnings on Apr 30, 2026.
IONS is expected to report earnings on Apr 29, 2026.
PFE is expected to report earnings on May 05, 2026.
Industries' Descriptions
@Biotechnology (+3.86% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
@Pharmaceuticals: Major (+1.10% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| INSM | IONS | PFE | |
| Capitalization | 30.8B | 12.4B | 157B |
| EBITDA | -1.18B | -273.12M | 16.8B |
| Gain YTD | -17.944 | -5.360 | 12.373 |
| P/E Ratio | N/A | N/A | 20.24 |
| Revenue | 606M | 944M | 62.6B |
| Total Cash | 1.43B | 2.68B | 13.6B |
| Total Debt | 587M | 2.07B | 64B |
INSM | IONS | PFE | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 64 | 8 | 75 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 76 Overvalued | 100 Overvalued | 34 Fair valued | |
PROFIT vs RISK RATING 1..100 | 37 | 45 | 100 | |
SMR RATING 1..100 | 100 | 98 | 74 | |
PRICE GROWTH RATING 1..100 | 49 | 41 | 27 | |
P/E GROWTH RATING 1..100 | 100 | 76 | 37 | |
SEASONALITY SCORE 1..100 | n/a | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
PFE's Valuation (34) in the Pharmaceuticals Major industry is somewhat better than the same rating for INSM (76) in the Biotechnology industry, and is significantly better than the same rating for IONS (100) in the Biotechnology industry. This means that PFE's stock grew somewhat faster than INSM’s and significantly faster than IONS’s over the last 12 months.
INSM's Profit vs Risk Rating (37) in the Biotechnology industry is in the same range as IONS (45) in the Biotechnology industry, and is somewhat better than the same rating for PFE (100) in the Pharmaceuticals Major industry. This means that INSM's stock grew similarly to IONS’s and somewhat faster than PFE’s over the last 12 months.
PFE's SMR Rating (74) in the Pharmaceuticals Major industry is in the same range as IONS (98) in the Biotechnology industry, and is in the same range as INSM (100) in the Biotechnology industry. This means that PFE's stock grew similarly to IONS’s and similarly to INSM’s over the last 12 months.
PFE's Price Growth Rating (27) in the Pharmaceuticals Major industry is in the same range as IONS (41) in the Biotechnology industry, and is in the same range as INSM (49) in the Biotechnology industry. This means that PFE's stock grew similarly to IONS’s and similarly to INSM’s over the last 12 months.
PFE's P/E Growth Rating (37) in the Pharmaceuticals Major industry is somewhat better than the same rating for IONS (76) in the Biotechnology industry, and is somewhat better than the same rating for INSM (100) in the Biotechnology industry. This means that PFE's stock grew somewhat faster than IONS’s and somewhat faster than INSM’s over the last 12 months.
| INSM | IONS | PFE | |
|---|---|---|---|
| RSI ODDS (%) | N/A | 1 day ago 73% | N/A |
| Stochastic ODDS (%) | 1 day ago 72% | 1 day ago 66% | 1 day ago 56% |
| Momentum ODDS (%) | 1 day ago 70% | 1 day ago 71% | 1 day ago 56% |
| MACD ODDS (%) | 1 day ago 70% | 1 day ago 77% | 1 day ago 62% |
| TrendWeek ODDS (%) | 1 day ago 72% | 1 day ago 66% | 1 day ago 55% |
| TrendMonth ODDS (%) | 1 day ago 74% | 1 day ago 74% | 1 day ago 51% |
| Advances ODDS (%) | 21 days ago 71% | 7 days ago 66% | 5 days ago 56% |
| Declines ODDS (%) | 6 days ago 73% | 9 days ago 65% | 12 days ago 57% |
| BollingerBands ODDS (%) | 1 day ago 70% | 1 day ago 67% | 1 day ago 58% |
| Aroon ODDS (%) | 1 day ago 82% | 1 day ago 75% | 1 day ago 53% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| SUSA | 143.81 | 0.02 | +0.01% |
| iShares ESG Optimized MSCI USA ETF | |||
| HPS | 14.64 | N/A | N/A |
| John Hancock Preferred Income Fund III | |||
| LJUL | 23.98 | N/A | N/A |
| Innovator Premium Income 15 Buf ETF -Jul | |||
| HISF | 44.95 | -0.01 | -0.03% |
| First Trust High Income Strat Foc ETF | |||
| BITU | 14.57 | -0.46 | -3.06% |
| ProShares Ultra Bitcoin ETF | |||